Daiichi Sankyo to Return Exclusive Development and Commercialization Rights for Four Diagnostic Imaging Agents to GE Healthcare in Japan

Daiichi Sankyo to Return Exclusive Development and Commercialization Rights for Four Diagnostic Imaging Agents to GE Healthcare in Japan

Shots:

  • Daiichi to return rights for four diagnostic imaging agents to GE Healthcare Omnipaque, Omniscan, including Visipaque, Sonazoid and the transfer of marketing authorization rights is expected to be complete in Mar’2020
  • GE Healthcare will be responsible for commercialization & regulatory activities for all four imaging agents. Daiichi will hold the rights to distribute the products till Mar’2022 and later transfer the rights to GE Healthcare
  • Omnipaque (Iohexol) is a contrast agent used in X-rays to visualize arteries, veins, ventricles of the brain, the urinary system & joints. Omniscan is a gadolinium-based contrast agent used in MRI to visualize lesions with abnormal vascularity. Sonazoid & Visipaque are the contrasting agent for ultrasonography and CT scans respectively

 Click here to read full press release/ article | Ref: Daiichi Sankyo | Image: Logos